[go: up one dir, main page]

IL169178A0 - Tiotropium containing hfc solution formulations - Google Patents

Tiotropium containing hfc solution formulations

Info

Publication number
IL169178A0
IL169178A0 IL169178A IL16917805A IL169178A0 IL 169178 A0 IL169178 A0 IL 169178A0 IL 169178 A IL169178 A IL 169178A IL 16917805 A IL16917805 A IL 16917805A IL 169178 A0 IL169178 A0 IL 169178A0
Authority
IL
Israel
Prior art keywords
solution formulations
containing hfc
hfc solution
tiotropium containing
tiotropium
Prior art date
Application number
IL169178A
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IL169178A0 publication Critical patent/IL169178A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL169178A 2002-12-16 2005-06-15 Tiotropium containing hfc solution formulations IL169178A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02028238 2002-12-16
PCT/EP2003/013692 WO2004054580A1 (en) 2002-12-16 2003-12-04 Tiotropium containing hfc solution formulations

Publications (1)

Publication Number Publication Date
IL169178A0 true IL169178A0 (en) 2007-07-04

Family

ID=32524008

Family Applications (1)

Application Number Title Priority Date Filing Date
IL169178A IL169178A0 (en) 2002-12-16 2005-06-15 Tiotropium containing hfc solution formulations

Country Status (13)

Country Link
EP (1) EP1575588A1 (en)
JP (1) JP2006510680A (en)
KR (1) KR20050085650A (en)
CN (1) CN1726038A (en)
AU (1) AU2003303029A1 (en)
BR (1) BR0317340A (en)
CA (1) CA2510043A1 (en)
IL (1) IL169178A0 (en)
MX (1) MXPA05006383A (en)
PL (1) PL375868A1 (en)
RU (1) RU2005122444A (en)
WO (1) WO2004054580A1 (en)
ZA (1) ZA200503546B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273603B2 (en) * 2003-07-11 2007-09-25 Boehringer Ingelheim International Gmbh HFC solution formulations containing an anticholinergic
NZ563596A (en) * 2005-05-02 2011-01-28 Boehringer Ingelheim Int Crystalline form of tiotropium bromide anhydrate
EP1879888A2 (en) * 2005-05-02 2008-01-23 Boehringer Ingelheim International GmbH Crystalline forms of tiotropium bromide
US9108962B2 (en) 2005-12-19 2015-08-18 Sicor, Inc. Forms of tiotropium bromide and processes for preparation thereof
MX2007009988A (en) * 2005-12-19 2008-02-22 Sicor Inc Novel forms of tiotropium bromide and processes for preparation thereof.
EP2201934A1 (en) 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Tiotropium aerosol formulation products with improved chemical stability
PE20121467A1 (en) 2009-12-23 2012-11-07 Chiesi Farma Spa AEROSOL FORMULATION FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
PE20121396A1 (en) 2009-12-23 2012-10-24 Chiesi Farma Spa PHARMACEUTICAL COMPOSITION INCLUDING GLYCOPYRONIUM BROMIDE AND FORMOTEROL
GB201200504D0 (en) * 2011-12-19 2012-02-22 Teva Branded Pharmaceutical Prod R & D Inc An inhaler
GB201200525D0 (en) * 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
JP6335798B2 (en) 2012-02-28 2018-05-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング New propellant-containing tiotropium formulation
CN104918604A (en) * 2012-10-23 2015-09-16 西普拉有限公司 Pharmaceutical composition
CA2930173A1 (en) * 2013-11-22 2015-05-28 Teva Branded Pharmaceutical Products R&D, Inc. An inhalable medicament
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
WO2018051132A1 (en) * 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
WO2018051128A1 (en) 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
WO2018051133A1 (en) 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
UA123919C2 (en) 2016-09-19 2021-06-23 Мехікем Флуор С.А. Де С.В. Pharmaceutical composition
GEP20217240B (en) * 2016-09-19 2021-03-25 Mexichem Fluor Sa De Cv Pharmaceutical composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG52459A1 (en) * 1992-12-09 1998-09-28 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations
DE10056104A1 (en) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Drug compositions useful for treatment of respiratory diseases, especially asthma and chronic obstructive pulmonary disease comprises tiotropium salts and salmeterol salts

Also Published As

Publication number Publication date
CA2510043A1 (en) 2004-07-01
RU2005122444A (en) 2007-01-27
AU2003303029A1 (en) 2004-07-09
MXPA05006383A (en) 2005-08-29
ZA200503546B (en) 2006-10-25
KR20050085650A (en) 2005-08-29
BR0317340A (en) 2005-11-08
CN1726038A (en) 2006-01-25
PL375868A1 (en) 2005-12-12
WO2004054580A1 (en) 2004-07-01
JP2006510680A (en) 2006-03-30
EP1575588A1 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
HRP20150039T1 (en) Pharmaceutical formulations containing methylnaltrexone
IL162642A0 (en) Formulations
ZA200503546B (en) Tiotropium containing HFC solution formulations
GB0302671D0 (en) Pharmaceutical formulations
GB0324886D0 (en) Medicinal compounds
GB0303396D0 (en) Medicinal compounds
GB0319874D0 (en) Novel formulation
EP1694278A4 (en) Glp-1 pharmaceutical compositions
IL172824A0 (en) Pharmaceutical formulations
IL171942A0 (en) Compositions containing ecteinascidin-743
GB0323701D0 (en) Formulations
EP1503804A4 (en) Radiopharmaceutical formulations
GB0302672D0 (en) Pharmaceutical formulations
ZA200508984B (en) Antifoaming formulations
GB0325383D0 (en) Oral formulations
GB0307765D0 (en) Tissue-adhesive formulations
GB0316341D0 (en) Pharmaceutical formulations
HRP20040889A2 (en) Hfa-suspension formulations containing an anticholinergic
IL174589A0 (en) Pharmaceutical compositions containing tetrahydrobiopterin
AU2003264443A8 (en) Preparation for external use
GB0214147D0 (en) Formulations
GB0316335D0 (en) Pharmaceutical formulations
SI1492513T1 (en) Hfa-suspension formulations containing an anticholinergic
GB0319551D0 (en) Formulations
GB0319549D0 (en) Formulations